Cargando…
Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)
In elderly patients (pts) with aggressive B cell lymphoma (aNHL), curative treatment often cannot be administered because of comorbidities and tolerability. We analyzed the influence of age in pts > 60 years receiving the R-CHOP-14 regimen within different prospective DSHNHL trials. Of the RICOVE...
Autores principales: | Zettl, Florian, Ziepert, Marita, Altmann, Bettina, Zeynalova, Samira, Held, Gerhard, Pöschel, Viola, Hohloch, Karin, Wulf, Gerald G., Glass, Bertram, Schmitz, Norbert, Loeffler, Markus, Trümper, Lorenz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960591/ https://www.ncbi.nlm.nih.gov/pubmed/33242101 http://dx.doi.org/10.1007/s00277-020-04345-3 |
Ejemplares similares
-
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL
por: Hohloch, Karin, et al.
Publicado: (2014) -
Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group
por: Hohloch, Karin, et al.
Publicado: (2020) -
Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
por: Borgerding, Andrea, et al.
Publicado: (2009) -
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis
por: Thieblemont, Catherine, et al.
Publicado: (2023) -
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
por: Braulke, Friederike, et al.
Publicado: (2022)